Abstract:Depression has severely impaired the health of the people all over the world. Cognitive dysfunction due to depression has exerted serious economic burden to family and society induced by the reduction of social functioning for patients. NDRIs targeted with norepinephrine transport (hNET) and distribution than dopamine transport (hDAT) simultaneously treat depression and improve cognitive function, and they effectively avoid sexual dysfunction and other side effects. However, the drugs of NDIRs are still performing poor response to many patients. So it is urgent to discover novel NDRIs antidepressants with the ability of improving the cognitive fuction. The aim of this work was to identify novel NDRIs candicates selectively against hNET and hDAT from large compound libraries by comprehensive strategy integrating SVM, ADME/T, molecular docking, vitro binding assays, molecular dynamics simulation and binding energy calculation. Firstly, 6,522 compounds without inhibiting serotonin transporter (hSERT) were hitted by SVM models of hNET, hDAT and non-target hSERT with similarities analysis from compound libraries. ADME/T and molecular docking were then used to filter compounds which could potently bind in hNET and hDAT with good ADME/T, and 4 compounds were successfully identified. According to their docking scors and ADME/T information, 3719810 was advanced for profiling in vitro assays as novel NDRIs lead compound attributing to its best druggability and balance activities. Encouragingly, 3719810 performed comparative activities on two targets with Ki value 7.32 μM for hNET and 5.23μM for hDAT. In order to abtain candicates with more activities and balance activities of 2 targets, 5 analogs were optimized and 2 novel scaffold compounds were successively designed. By assessment of molecular docking, molecular dynamics simulation and binding energy calculation, 5 compounds were validated as NDRIs candicates with high activties, and 4 out of them performed acceptable balance actives acting on hNET and hDAT, which could supply promising novel NDRIs to exploit drugs for depression with cognitive dysfunction or other related neruodegenrative disorders, and also shed sight on screening inhibitors for dual-target with homological non-target on highly efficient and cost-effective.

SKF83959 is a Novel Triple Reuptake Inhibitor That Elicits Anti-Depressant Activity

A Novel Dual Serotonin Transporter and M-channel Inhibitor D01 for Antidepression and Cognitive Improvement

SKF83959 Produces Antidepressant Effects in a Chronic Social Defeat Stress Model of Depression Through BDNF-TrkB Pathway.

SKF83959 is a Potent Allosteric Modulator of Sigma-1 Receptor

In Vitro and in Vivo Characterization of PA01, a Novel Promising Triple Reuptake Inhibitor.

Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues.

Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template

Pharmacological Characterization of H05, a Novel Serotonin and Noradrenaline Reuptake Inhibitor with Moderate 5-HT2A Antagonist Activity for the Treatment of Depression.

A Multiple-step Screening Protocol to Identify Norepinephrine and Dopamine Reuptake Inhibitors for Depression

SKF83959 Suppresses Excitatory Synaptic Transmission in Rat Hippocampus Via a Dopamine Receptor-Independent Mechanism.

Discovery of N-methyl-1-(1-phenylcyclohexyl)methanamine, a novel triple serotonin, norepinephrine, and dopamine reuptake inhibitor.

Discovery of N-methyl-1-(1-phenylcyclohexyl)ethanamine, a Novel Triple Serotonin, Norepinephrine and Dopamine Reuptake Inhibitor

The Effects of LPM570065, a Novel Triple Reuptake Inhibitor, on Extracellular Serotonin, Dopamine and Norepinephrine Levels in Rats

Synthesis and pharmacological evaluation of 4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalenyl amines as triple reuptake inhibitors.

Exploration of 1-(4-(7-Azaindole)-3,6-dihydropyridin-1-yl)alkyl-3-(1H-indol-3-yl)pyrrolidine-2,5-dione Derivatives with Affinity for the Serotonin Transporter

Design, Synthesis, and Functional Evaluation of 1, 5-Disubstituted Tetrazoles as Monoamine Neurotransmitter Reuptake Inhibitors

Design, synthesis and biological evaluation of arylpropylamine derivatives as potential multi-target antidepressants

Synthesis and evaluation of novel 2,3-dihydrobenzo[b][1,4]dioxin- and indolealkylamine derivatives as potential antidepressants.

The Potent and Selective Α4β2/α6-Nicotinic Acetylcholine Receptor Partial Agonist 2-[5-[5-((s)azetidin-2-ylmethoxy)-3-pyridinyl]-3-isoxazolyl]ethanol Demonstrates Antidepressive-Like Behavior in Animal Models and a Favorable ADME-tox Profile.

Synthesis and biological evaluation of multimodal monoaminergic arylpiperazine derivatives with potential antidepressant profile

The Paradoxical Effects of Skf83959, A Novel Dopamine D-1-Like Receptor Agonist, in The-Rat Acoustic Startle Reflex Paradigm